

Najmeh Moradi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9178969/publications.pdf>

Version: 2024-02-01

27
papers

232
citations

1163117

8
h-index

1058476

14
g-index

33
all docs

33
docs citations

33
times ranked

301
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Effectiveness of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy Versus Systematic Transrectal Ultrasound-Guided Biopsy for Prostate Cancer Diagnosis: A Systematic Review. <i>Value in Health Regional Issues</i> , 2022, 30, 31-38.	1.2	3
2	Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. <i>Archives of Iranian Medicine</i> , 2021, 24, 139-143.	0.6	21
3	Willingness to pay for and acceptance of cervical cancer prevention methods: A systematic review and meta-analysis. <i>Medical Journal of the Islamic Republic of Iran</i> , 2021, 35, 81.	0.9	2
4	Public Views on Priority Groups for COVID-19 Vaccination: A Survey from Iran. <i>Shiraz E Medical Journal</i> , 2021, 22, .	0.3	2
5	Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 35.	1.5	8
6	The effect of risk communication on preventive and protective Behaviours during the COVID-19 outbreak: mediating role of risk perception. <i>BMC Public Health</i> , 2021, 21, 54.	2.9	68
7	Barriers and Drivers of Public Preventive Behavioral Responses to COVID-19 Outbreak: Evidence from Iran. <i>Health Scope</i> , 2021, 10, .	0.6	4
8	Private Demand for Covid-19 Vaccine: A Contingent Assessment from a Low-and Middle-income Country.. <i>Iranian Journal of Pharmaceutical Research</i> , 2021, 20, 223-234.	0.5	4
9	Men's willingness to pay for prostate cancer screening: a systematic review. <i>Systematic Reviews</i> , 2020, 9, 290.	5.3	9
10	An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 47.	1.5	4
11	Evaluating the preventive and curative effects of <i>Toxocara canis</i> larva in Freund's complete adjuvant-induced arthritis. <i>Parasite Immunology</i> , 2020, 42, e12760.	1.5	3
12	Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1710.	2.6	6
13	An application of analytic network process model in supporting decision making to address pharmaceutical shortage. <i>BMC Health Services Research</i> , 2020, 20, 626.	2.2	6
14	Affordability of Medication Therapy in Diabetic Patients: A Scenario-Based Assessment in Iran's Health System Context. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.9	3
15	Managing Pharmaceutical Expenditures: Estimating the Effect of Internal Reference Pricing for Three Pharmacological Categories. <i>Avicenna Journal of Pharmaceutical Research</i> , 2020, 1, 76-81.	0.0	0
16	COVID-19: The Challenge of Disadvantaged Groups and their Access to Care. <i>Archives of Iranian Medicine</i> , 2020, 23, 647-648.	0.6	0
17	High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection. <i>Archives of Virology</i> , 2019, 164, 2493-2504.	2.1	15
18	The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method. <i>PharmacoEconomics - Open</i> , 2019, 3, 311-319.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2019, 27, 169-177.	2.0	12
20	Willingness to pay for one quality-adjusted life year in Iran. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 4.	1.5	13
21	Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users. <i>Archives of Virology</i> , 2019, 164, 349-357.	2.1	7
22	Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 837-846.	2.1	13
23	Health State Utilities for Patient's Current Health from Bipolar Type I Disorder. <i>Journal of Mental Health Policy and Economics</i> , 2018, 21, 3-10.	0.6	2
24	How to Maintain Pharmaceutical Access in Crisis: The Iran FDA Experience. <i>Value in Health</i> , 2017, 20, A665-A666.	0.3	0
25	Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP). <i>Iranian Journal of Pharmaceutical Research</i> , 2017, 16, 823-833.	0.5	9
26	Willingness to Pay for Complementary Health Care Insurance in Iran. <i>Iranian Journal of Public Health</i> , 2017, 46, 1247-1255.	0.5	3
27	Willingness to Pay for One Quality Adjusted Life Years In Patients With Diabetes. <i>Value in Health</i> , 2015, 18, A616-A617.	0.3	6